Inhibitors Increase AUC of sensitive substrates of P gp e g dabigatran digoxin edoxaban 1 2 fold

By rray, 7 February, 2024
Exclude Patient Type Detail Header
No
Detail Type
Text
Detail Text
abrocitinib
adagrasib
amiodarone
atorvastatin
azithromycin
berotralstat
bisoprolol
canagliflozin
cannabidiol
capmatinib
captopril
carvedilol
cimetidine
clarithromycin
cobicistat
conivaptan
cyclosporine
daridorexant
darunavir
dasabuvir
diltiazem
diosmin
dronedarone
elacestrant
elagolix
elexacaftor tezacaftor ivacaftor
eliglustat
enasidenib
entrectinib
enzalutamide
erythromycin base
etravirine
felodipine
flibanserin
fluvoxamine
fostamatinib
ginkgo
glecaprevir
hydroxychloroquine sulfate
ibrutinib
indomethacin
isavuconazonium sulfate
istradefylline
itraconazole
ivacaftor
ketoconazole
lapatinib
lasmiditan
ledipasvir
lenacapavir
levoketoconazole
lonafarnib
lopinavir ritonavir
lumacaftor ivacaftor
maribavir
mifepristone
milk thistle Silybum marianum
mirabegron
naproxen
nefazodone
nelfinavir
neratinib
nifedipine
nisoldipine
osimertinib
paritaprevir
paroxetine
pibrentasvir
pirtobrutinib
posaconazole
propafenone
quercetin
quinidine sulfate
quinidine CYP2D6 inhibitor
quinine sulfate
ranolazine
ritonavir
rolapitant
rucaparib
saquinavir
sarecycline
selpercatinib
simvastatin
sotagliflozin
sotorasib
suvorexant
telmisartan
tepotinib
tezacaftor ivacaftor
ticagrelor
tipranavir
tolvaptan
trazodone
trimethoprim
tucatinib
turmeric Curcuma longa
valbenazine
vandetanib
velpatasvir
vemurafenib
venetoclax
verapamil
vilazodone
voclosporin
voxilaprevir
Patient Type Detail Header (Long)
<b>Inhibitors:</b> Increase AUC of sensitive substrates of P-gp (e.g., dabigatran, digoxin, edoxaban) <b>≥1.2-fold:</b>